Our analysis provides valuable insights into the potential benefits of sacubitril/valsartan in enhancing post-myocardial infarction (MI) outcomes, specifically in relation to the left ventricle ejection fraction (LVEF), N-terminal (NT) pro-B-type natriuretic peptide (BNP) levels, rehospitalization rates, and major adverse cardiac events (MACE). This evidence concerns the gene NPPB and myocardial infarction.